Pretreatment Serum Level of Neuron Specific Enolase (NSE) as a Prognostic Factor in Metastatic Prostate Cancer Patients Treated with Endocrine Therapy

By Kamiya N.   Akakura K.   Suzuki H.   Isshiki S.   Komiya A.   Ueda T.   Ito H.  

European Urology, Vol. 44, Iss. 3, 2003-09 ,pp. : 309-314

Elsevier

Access to resources Recommend Favorite

Increase of bone alkaline phosphatase after androgen deprivation therapy in patients with prostate cancer

By Morote J.   M'Hammed Y.I.D.   Martinez E.   Esquena S.   Lorente J.A.   Gelabert A.  

Urology, Vol. 59, Iss. 2, 2002-02 ,pp. : 277-280

Elsevier

Access to resources Recommend Favorite

Prognostic indicators for response to therapy and survival in patients with metastatic renal cell cancer treated with interferon alpha-2 beta and vinblastine

By Papadopoulos I.   Rudolph P.   Weichert-Jacobsen K.   Thiemann O.   Papadopoulou D.  

Urology, Vol. 48, Iss. 3, 1996-09 ,pp. : 373-378

Elsevier

Access to resources Recommend Favorite

Side-effects of post-treatment biopsies in prostate cancer patients treated with endocrine therapy alone or combined with radical radiotherapy in the Scandinavian Prostate Cancer Group-7 randomized trial

By Solberg Arne   Widmark Anders   Tasdemir Ilker   Ahlgren Göran   Angelsen Anders  

Scandinavian Journal of Urology and Nephrology, Vol. 45, Iss. 4, 2011-09 ,pp. : 233-238

Informa Healthcare

Access to resources Recommend Favorite

The prognostic importance of prostate specific antigen in the monitorisation of patients undergoing maximum androgen blockade for metastatic prostate cancer

By Kiper Ahmet   Yiğitbası Orhan   Imamoglu Abdurrahim   Tuygun Can   Turan Celaleddin  

International Urology and Nephrology, Vol. 38, Iss. 3-4, 2006-12 ,pp. : 571-576

Springer Publishing Company

Access to resources Recommend Favorite